We Are Approaching the Half-Way Mark!

To date we have raised $922.

We have not been diligent at updating the blog.  Updates have been posted at herpes-coldsores.com. We will try to update the blog regularly.  

Since our grassroots fundraising event started (Christmas Day 2008), we have raised over $900!  In less than one month we have raised close to half of our goal of $2000.  Yes, I am aware that $2000 is not enough money to find a vaccine or cure for HSV.  However, this is just a small part of the major goal.  The University of Florida requires an initial donation of $2000 to establish an online donation system for the HSV researchers.  Once established then Dr. Bloom will be able to receive donations online at the University.  But in order for Dr. Bloom to start receiving to donations, we need to do our part, which is to raise the minimum requirement that will help establish Dr. Bloom's research fund for online contributions.

The U of Fl HSV research lead by Dr. David Bloom has developed a novel method of preventing recurrence of HSV.  To learn about the Novel Method for Preventing Recurrence of Herpes Simplex Virus at U of Fl....... (first entry to the thread on the message board). Also, from a much more scientific perspective, read about U of Fl, Hammerhead Ribozymes (1) and (2).

Also, the following is an excerpt taken from the thread (link above) at herpes-coldsores.com regarding the status of Dr. Bloom's research.

***

The ribozymes created for HSV1 is ready for clinical trials. When research is at this stage, it is waiting for someone to purchase rights to use it for clinicals. Unless venture capitalists or big pharma purchases the rights, it can sit for years.

The ribozyme study for HSV2 is in pre-clinical study. David Bloom needs funding for this study. There is currently no funding for it. To complete the study it will take $200,000. The good news is that once they complete the study and it is ready for clinical trials, venture capitalists are waiting to purchase the rights to take it to clinical. The venture capitalists are more interested in purchasing the rights for this study because they feel it is more marketable and there will be more interest from the public.

David Bloom is developing a website that will link to his homepage. The website will contain information about both the HSV1 Ribozyme study and HSV2 Ribozyme study. The website will contain a link to allow the people to contribute to the research. He will provide updates on the project and the amount of money raised.

***